ICIL-1RA en es it fr

ICIL-1RA Brand names, ICIL-1RA Analogs

ICIL-1RA Brand Names Mixture

  • No information avaliable

ICIL-1RA Chemical_Formula


ICIL-1RA RX_link


ICIL-1RA fda sheet

ICIL-1RA msds (material safety sheet)

ICIL-1RA Synthesis Reference

No information avaliable

ICIL-1RA Molecular Weight


ICIL-1RA Melting Point

No information avaliable

ICIL-1RA H2O Solubility

No information avaliable

ICIL-1RA State




ICIL-1RA Dosage Forms


ICIL-1RA Indication

For treatment of adult rheumatoid arthritis

ICIL-1RA Pharmacology

Used to treat rheumatoid arthritis, Kineret blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs.1 IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.

ICIL-1RA Absorption

No information avaliable

ICIL-1RA side effects and Toxicity

No information avaliable

ICIL-1RA Patient Information


ICIL-1RA Organisms Affected

Humans and other mammals